China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays

 
• By Dexter Jie Yan

The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.

China’s Lead mRNA COVID-19 Vaccine Candidate Faces Delays
ARCoV has run into delays in a global multi-center Phase III study • Source: Alamy

More from China

More from Focus On Asia